patient subgroup...
age >= 60 yr age >= 65 yr corticosteroids: no corticosteroids: yes invasive ventilation non invasive oxygen subjects at risk
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
antiviral and associated therapy - versus antiviral and associated therapy - for COVID 19 hospitalized
method
abbreviations
Outcome
Relative effect 95%CI
LoD
Trt. better when
I2
k (RCT/OBS)
Bayesian probability
Overall ROB
Publication bias
Degree of certainty
Endpoint importance
Published MA
00 death D28 0.12 [0.02, 0.62]< 1 0% 1 study (1/-) 99.4 % NA not evaluable crucial - death or transfer to ICU 1.02 [0.02, 52.72]< 1 0% 1 study (1/-) 49.6 % NA not evaluable crucial - deaths 0.98 [0.63, 1.53]< 1 31% 10 studies (9/1) 52.8 % moderate low moderate crucial - deaths (time to event analysis only) 0.94 [0.51, 1.73]< 1 0% 1 study (1/-) 57.9 % NA not evaluable crucial - clinical deterioration 1.07 [0.63, 1.82]< 1 0% 1 study (1/-) 40.2 % NA not evaluable important - clinical improvement 1.49 [0.64, 3.48]> 1 86% 3 studies (3/-) 82.3 % some concern not evaluable moderate important - clinical improvement (14-day) 1.48 [1.05, 2.08]> 1 0% 2 studies (2/-) 98.8 % some concern not evaluable moderate important - clinical improvement (7-day) 1.46 [0.95, 2.23]> 1 0% 1 study (1/-) 95.8 % NA not evaluable important - clinical improvement (time to event analysis only) 1.15 [0.70, 1.87]> 1 84% 3 studies (3/-) 70.9 % some concern not evaluable moderate important - hospital discharge 1.08 [0.56, 2.09]> 1 71% 3 studies (2/1) 59.1 % low not evaluable high important - mechanical ventilation 0.53 [0.05, 5.86]< 1 87% 2 studies (2/-) 69.5 % some concern not evaluable moderate important - radiologic improvement (14-day) 2.56 [0.56, 11.82]> 1 80% 2 studies (2/-) 88.6 % low not evaluable high important - radiologic improvement (7-day) 0.42 [0.01, 17.35]> 1 74% 2 studies (2/-) 32.5 % some concern not evaluable moderate important - viral clearance 1.46 [0.64, 3.33]> 1 76% 4 studies (4/-) 81.6 % some concern not evaluable moderate important - viral clearance (time to event analysis only) 2.39 [0.79, 7.19]> 1 77% 2 studies (2/-) 93.9 % high not evaluable low important - viral clearance by day 14 1.10 [0.95, 1.26]> 1 0% 2 studies (2/-) 89.5 % some concern not evaluable moderate important - viral clearance by day 7 0.82 [0.28, 2.35]> 1 58% 3 studies (3/-) 35.3 % some concern not evaluable moderate important - ICU admission 0.83 [0.34, 2.04]< 1 74% 3 studies (3/-) 65.9 % low not evaluable high non important - recovery 2.23 [0.23, 21.31]> 1 87% 2 studies (2/-) 75.6 % low not evaluable high non important - severe COVID-19 occurrence 0.30 [0.07, 1.27]< 1 0% 1 study (1/-) 94.9 % NA not evaluable non important - 00 serious adverse events 0.43 [0.03, 5.81]< 1 0% 2 studies (2/-) 73.6 % some concern not evaluable moderate important - adverse events 0.51 [0.06, 4.06]< 1 68% 4 studies (4/-) 73.6 % low not evaluable high non important - serious adverse events (SAE), any 0.50 [0.32, 0.79]< 1 0% 1 study (1/-) 99.9 % NA not evaluable non important -
LoD: level of statistical demonstration:
